(PTI) - Earnings & Price History

PTI: - 1.89, $47.44M, 0.00 (0.00%)

Sector: Technology - Industry: Application Software

Proteostasis Therapeutics, Inc., a biopharmaceutical company, develops therapeutics to treat protein conformational diseases. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class. The company is also developing PTI-NC-733, a novel combination therapy; and PTI-130 for the treatment of chronic obstructive pulmonary disease. It has strategic alliance with Biogen New Ventures Inc. to enhance the clearance of misfolded aggregation-prone proteins in neurodegenerative diseases, such as in Alzheimers and Parkinsons disease; and Astellas Pharma Inc. to research, develop, and commercialize therapies targeting unfolded protein response. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was

Past PTI reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2016-11-10-0.49

Login | Register
Saturday Nov 17, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades